Ajooni Biotech Limited (NSE: AJOONI)
India
· Delayed Price · Currency is INR 8.45
+0.09 (1.08%)
Sep 27, 2024, 3:29 PM IST
Ajooni Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Operating Revenue | 847.7 | 801.15 | 744.88 | 740.38 | 510.39 | 400.33 | Upgrade
|
| Other Revenue | - | 1.39 | - | - | - | - | Upgrade
|
| Revenue | 847.7 | 802.54 | 744.88 | 740.38 | 510.39 | 400.33 | Upgrade
|
| Revenue Growth (YoY) | 1.91% | 7.74% | 0.61% | 45.06% | 27.49% | 0.79% | Upgrade
|
| Cost of Revenue | 739.84 | 703.5 | 657.43 | 640.13 | 430.13 | 349.12 | Upgrade
|
| Gross Profit | 107.87 | 99.04 | 87.45 | 100.24 | 80.26 | 51.21 | Upgrade
|
| Selling, General & Admin | 18.37 | 64.3 | 50.88 | 56.03 | 51.83 | 32.44 | Upgrade
|
| Other Operating Expenses | 64.18 | 7.06 | 6.8 | 11.57 | 11.77 | 6.17 | Upgrade
|
| Operating Expenses | 91.43 | 80.1 | 67.73 | 78.7 | 69.37 | 43.53 | Upgrade
|
| Operating Income | 16.43 | 18.94 | 19.72 | 21.54 | 10.89 | 7.68 | Upgrade
|
| Interest Expense | -5.73 | - | - | - | - | - | Upgrade
|
| Interest & Investment Income | - | 5.06 | 2.05 | 0.01 | 0 | 0.73 | Upgrade
|
| Other Non Operating Income (Expenses) | 21.58 | -5.3 | -4.77 | -5.4 | -5.84 | -3.28 | Upgrade
|
| EBT Excluding Unusual Items | 32.28 | 18.7 | 16.99 | 16.15 | 5.05 | 5.13 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | -0.32 | Upgrade
|
| Other Unusual Items | - | -1.95 | -1.23 | -1.54 | -0.01 | - | Upgrade
|
| Pretax Income | 32.28 | 29.96 | 15.77 | 14.61 | 5.04 | 4.81 | Upgrade
|
| Income Tax Expense | 10 | 8.35 | 4.52 | 4.12 | 1.31 | 1.34 | Upgrade
|
| Net Income | 22.28 | 21.61 | 11.25 | 10.49 | 3.73 | 3.47 | Upgrade
|
| Net Income to Common | 22.28 | 21.61 | 11.25 | 10.49 | 3.73 | 3.47 | Upgrade
|
| Net Income Growth | 84.93% | 92.16% | 7.24% | 181.14% | 7.57% | -15.62% | Upgrade
|
| Shares Outstanding (Basic) | 121 | 88 | 60 | 51 | 50 | 47 | Upgrade
|
| Shares Outstanding (Diluted) | 121 | 88 | 60 | 51 | 50 | 47 | Upgrade
|
| Shares Change (YoY) | 593.01% | 46.51% | 18.35% | 1.00% | 6.46% | 37.90% | Upgrade
|
| EPS (Basic) | 0.18 | 0.25 | 0.19 | 0.21 | 0.07 | 0.07 | Upgrade
|
| EPS (Diluted) | 0.18 | 0.25 | 0.19 | 0.21 | 0.07 | 0.07 | Upgrade
|
| EPS Growth | -73.31% | 31.15% | -9.39% | 180.50% | 0.27% | -38.81% | Upgrade
|
| Free Cash Flow | - | -56.6 | -69.39 | 15.6 | -23.71 | -57.86 | Upgrade
|
| Free Cash Flow Per Share | - | -0.65 | -1.16 | 0.31 | -0.47 | -1.23 | Upgrade
|
| Gross Margin | 12.72% | 12.34% | 11.74% | 13.54% | 15.73% | 12.79% | Upgrade
|
| Operating Margin | 1.94% | 2.36% | 2.65% | 2.91% | 2.13% | 1.92% | Upgrade
|
| Profit Margin | 2.63% | 2.69% | 1.51% | 1.42% | 0.73% | 0.87% | Upgrade
|
| Free Cash Flow Margin | - | -7.05% | -9.32% | 2.11% | -4.65% | -14.45% | Upgrade
|
| EBITDA | 24.85 | 27.68 | 29.77 | 31.24 | 15.26 | 11.19 | Upgrade
|
| EBITDA Margin | 2.93% | 3.45% | 4.00% | 4.22% | 2.99% | 2.80% | Upgrade
|
| D&A For EBITDA | 8.42 | 8.74 | 10.05 | 9.7 | 4.37 | 3.51 | Upgrade
|
| EBIT | 16.43 | 18.94 | 19.72 | 21.54 | 10.89 | 7.68 | Upgrade
|
| EBIT Margin | 1.94% | 2.36% | 2.65% | 2.91% | 2.13% | 1.92% | Upgrade
|
| Effective Tax Rate | 30.99% | 27.87% | 28.68% | 28.22% | 26.02% | 27.86% | Upgrade
|
| Revenue as Reported | 869.28 | 823.08 | 747.82 | 740.76 | 510.56 | 400.92 | Upgrade
|
| Advertising Expenses | - | 0.36 | 0.19 | 0.35 | 0.13 | 0.96 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.